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formalin-inactivated preparations developed by Jonas Salk
which were extensively used beginning in the mid 1950s.
The live attenuated strains developed by Albert Sabin were
introduced in the early 1960s, largely because of the diffi-
culties of producing sufficient killed virus vaccine with the
technology of the time and they remain the most widely
used globally. The live strains infect the recipient and in-
duce immunity, and while paralytic disease due to the
vaccine can occur, its incidence is extremely low, being
estimated at 1 per 530,000 first-time vaccinees. Live vac-
cines have the advantage that they induce the full range of
immune responses and have always been the vaccine of
choice for the interruption of epidemics, because they pre-
vent infection of the intestine either by inducing intestinal
immunity or by competing with the epidemic strain for
susceptible individuals.
THE ERADICATION PROGRAM
WHO has declared the target of eradicating poliomy-
elitis due to wild-type poliovirus from the world by the
year 2000. The progress to this end is extraordinary,
particularly as up until 20 years ago experience sug-
gested that the live attenuated vaccine (oral poliovac-
cine, OPV) was not effective in tropical countries. The
low efficacy was probably the result of two factors. First,
the quality of the vaccine used was almost certainly poor
because of lack of adequate cold storage in countries
which were not only not wealthy but also hot. Second,
exposure to the virus is seasonal in temperate climates,
but continuous in tropical countries; by vaccinating chil-
dren when they reach a set age as in most vaccination
programs in temperate climates, it is therefore possible
to reduce the number of susceptibles during the nonepi-
demic season to such an extent that transmission of the
wild-type strain is interrupted. In contrast, in countries
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231where exposure is continuous it is a matter of chance
whether the child is exposed to vaccine or wild-type virus
first and transmission continues. The successful strategy
developed in South America in the 1970s and 1980s was
first proposed by Sabin in 1960 (Sabin et al., 1960). It
involves saturating the area with vaccine over a short
period so that every susceptible individual is infected
with the vaccine strain rather than wild-type strains
whose transmission is therefore blocked. This has
evolved into national immunization days (NIDs) where,
for example, China immunized one-quarter of the world’s
children in a single week in 1992, and India immunized
130 million children in a single day in 1998, repeating the
exercise twice in the same year. The results are that the
whole of the Americas is now certified free of wild-type
polio, the last case occurring in 1992, and that China and
the whole Western Pacific Region have not had a case of
polio attributable to indigenous wild-type virus since
March 1997. There is every reason to believe that this
kind of progress will continue and that the virus will be
eradicated from India/Pakistan, Africa, and the Eastern
Mediterranean in the immediate future. Progress reports
can be found on the WHO website (http://whqsabin.
who.int.8082/). In practical terms, it will be essential to be
sure that the virus has really been eradicated, and sur-
veillance is the cornerstone of future developments.
SURVEILLANCE
Strains of poliovirus can be identified by limited se-
quencing of their genomes, and it was established early
on (Ricoh-Hesse et al., 1987) that the sequences could
be grouped such that strains from the same geographi-
cal areas formed clusters or genotypes largely indepen-
dent of their year of isolation. By analyzing isolates in this
way it is therefore possible to follow the gradual elimi-
nation of lineages of virus in a region as the vaccination
program has its effect and to identify strains as indige-
nous or imported from other geographical areas. Ulti-
mately wild-type viruses will no longer be isolated, type
2 disappearing first, followed by type 1 and then type 3.
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vaccination program is effective but do not in themselves
show that the virus has been eradicated altogether, only
that it is increasingly difficult to find.
Different types of surveillance schemes have been
proposed. Poliomyelitis is one of several forms of acute
flaccid paralysis (AFP). If an AFP surveillance system is
put in place it should therefore detect a minimum base-
line level of paralysis due to causes other than polio and
the figure quoted is one case per 100,000 head of pop-
ulation. If all cases are investigated and shown not to be
caused by poliovirus, and if this background incidence is
reached, then the surveillance system is considered ad-
equate to demonstrate the absence of polio. This has
been achieved in several countries. In the United King-
dom, however, although there was no detectable polio-
myelitis due to wild-type virus, the figures reached were
well below the target level despite strenuous efforts,
implying either that the background rate is not uniform
across the world or, more likely, that it can be difficult to
achieve good clinical surveillance for this purpose.
An alternative approach to surveillance relies on the
examination of polio viruses isolated in the course of
clinical or environmental studies. Isolates should be
shown to be vaccine derived, not wild type. A single case
of poliomyelitis usually reflects at least a hundred silently
infected individuals, so that this method might be fairly
sensitive. It depends crucially on the number of isolates
made and the vigor of environmental virological studies
and can therefore also be criticized.
Any surveillance system will have difficulties with ar-
eas of a country which are not readily accessible for
either geographical or political/military reasons. There
are recent examples of foci of infection being detected in
countries with otherwise good surveillance systems be-
cause of difficulties of this nature.
MECHANISMS FOR THE REEMERGENCE
OF POLIOMYELITIS
Once poliomyelitis due to wild-type virus is known to
be eradicated, the most common source of poliovirus
infection will be the live vaccine. At some stage vacci-
nation will stop and it is necessary to consider whether
poliomyelitis could come back. There are a number of
possibilities of varying degrees of probability. First, it is
possible that foci of infection will have been missed
because of difficulties intrinsic to surveillance systems.
Second, poliovirus is widespread in laboratories and
manufacturing facilities and may be present in clinical
specimens taken for other purposes. The virus has been
shown to escape from vaccine-manufacturing plants un-
der current conditions on at least two occasions. Steps
are currently being taken to contain laboratory and other
stocks, which is not a trivial exercise. Third, while it is
generally accepted that there is no animal reservoir for
poliovirus, it is known that certain strains can paralyzemice under appropriate conditions, and it is at least
theoretically possible that any existing animal reservoir
is masked by the far larger and more effective reservoir
in humans. Fourth, poliovirus is a member of the entero-
virus genus of the picornaviridae family, and some other
enteroviruses, notably coxsackie A viruses, are very
closely related to poliovirus at the molecular level
(Hyypia¨ et al., 1997). It is conceivable that an enterovirus
could adapt so that it uses the receptor site for poliovirus
on the susceptible cell and therefore evolve to reoccupy
the poliovirus niche, presumably also causing paralysis.
The numbers of mutations required to do this and their
effects when introduced singly are being studied. Fifth, it
has been known for many years that individuals unable
to mount a humoral immune response are particularly at
risk from infection with enteroviruses in general and
poliovirus in particular. Moreover, they can be infected
for prolonged periods, sometimes for several years, with-
out obvious ill effects. Such patients could form a source
of infection which would become increasingly dangerous
as the susceptibility of the surrounding population in-
creases. The extent to which immunodeficient individu-
als are infected with poliovirus is not known, although it
is being actively investigated. It is also possible that
those whose immunodeficiency is not serious enough to
attract medical investigation could be affected. Finally,
bioterrorism is a possibility. The RNA genome of polio-
virus is infectious and numerous publications have noted
sequences of different strains. As it is only 7.5 kb in
length it would be possible to synthesize it even with
today’s technology; while such an exercise is currently
unlikely because of the number of strains freely avail-
able, in 20 years it may not be.
CONCLUSIONS
For a variety of reasons it will be necessary to main-
tain stocks of poliovaccines of some kind after poliomy-
elitis is eradicated. The form such vaccines take and the
size of the stocks needed are undecided at present. The
progress toward eradication has been dramatic and the
fact that consideration must be given to mechanisms for
stopping vaccination and routes by which polio could
return is a tribute to the success of the efforts directed
toward its elimination.
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